---
title: "Bioxytran sees positive dose optimization, moves to Phase 3 trial for ProLectin-M with 408 patients, targeting viral infected outpatients."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277831578.md"
description: "A company has begun regulatory discussions with the Central Drugs Standard Control Organization (CDSCO). They are planning to conduct a pivotal study with 408 patients focusing on standard-risk outpatients infected with various viruses."
datetime: "2026-03-04T20:42:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277831578.md)
  - [en](https://longbridge.com/en/news/277831578.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277831578.md)
generator: "portal-rs"
---

# Bioxytran sees positive dose optimization, moves to Phase 3 trial for ProLectin-M with 408 patients, targeting viral infected outpatients.

A company has begun regulatory discussions with the Central Drugs Standard Control Organization (CDSCO). They are planning to conduct a pivotal study with 408 patients focusing on standard-risk outpatients infected with various viruses.

### Related Stocks

- [BIXT.US](https://longbridge.com/en/quote/BIXT.US.md)

## Related News & Research

- [Mirum Pharmaceuticals (MIRM) Following Rare Disease Growth Narrative Looks Undervalued](https://longbridge.com/en/news/296924108.md)
- [10:31 ETLiver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight](https://longbridge.com/en/news/296802956.md)
- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [Can Komzifti's Early Adoption Support Kura Oncology's Next Phase Of Growth?](https://longbridge.com/en/news/296928079.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**